PE20090434A1 - Derivados de sulfonil amida como inhibidores de quinasas - Google Patents
Derivados de sulfonil amida como inhibidores de quinasasInfo
- Publication number
- PE20090434A1 PE20090434A1 PE2008000674A PE2008000674A PE20090434A1 PE 20090434 A1 PE20090434 A1 PE 20090434A1 PE 2008000674 A PE2008000674 A PE 2008000674A PE 2008000674 A PE2008000674 A PE 2008000674A PE 20090434 A1 PE20090434 A1 PE 20090434A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- methyl
- pyrimidin
- pyridin
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
REFERIDA A UN DERIVADO DE SULFONILAMIDA DE FORMULA (I), DONDE A ES UN ANILLO CARBOCICLICO DE 4 A 7 MIEMBROS, UN ANILLO HETEROCICLICO DE 4 A 7 MIEMBROS, FENILO, ENTRE OTROS; B ES FENILO O UN HETEROARILO DE 5 A 6 MIEMBROS; R1 ES H, HALO, CF3, CN, ENTRE OTROS; R2 Y R3 SON H, ALO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R4 Y R5 SON H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R6 ES HALO, NO2, ALQUILO C1-C6, ENTRE OTROS; K ES CH, C(NH2) O N; n ES UN ENTERO DE 1 A 3; m ES UN ENTERO DE 0 A3. SON COMPUESTOS PREFERIDOS: (R)-N-(3-((2-(4-(1-AMINOETIL)FENILAMINO)-5-(TRIFLUOROMETIL)PIRIMIDIN-4-ILAMINO)METIL)PIRIDIN-2-IL)-N-METILMETANO-SULFONAMIDA, N-(3-((2-(4-(AMINOMETIL)FENILAMINO)-5-(TRIFLUOROMETIL)PIRIMIDIN-4-ILAMINO)METIL)PIRIDIN-2-IL)-N-METILMETANO-SULFONAMIDA, N-[4-({4-[({2-[METIL(METILSULFONIL)AMINO]PIRIDIN-3-IL}METIL)AMINO]-5-(TRIFLUOROMETIL)PIRIMIDIN-2-IL}AMINO)BENCIL]ACETAMID, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA E INHIBIDORES DE LA TIROSINA QUINASA NO RECEPTORA, FAK, AURORA, PyK, HgK Y SON UTILES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91259707P | 2007-04-18 | 2007-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090434A1 true PE20090434A1 (es) | 2009-04-13 |
Family
ID=39646361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000674A PE20090434A1 (es) | 2007-04-18 | 2008-04-17 | Derivados de sulfonil amida como inhibidores de quinasas |
Country Status (33)
Country | Link |
---|---|
US (12) | US7928109B2 (es) |
EP (1) | EP2146779B1 (es) |
JP (1) | JP4782239B2 (es) |
KR (1) | KR101132880B1 (es) |
CN (2) | CN103951658B (es) |
AP (1) | AP2009005010A0 (es) |
AR (1) | AR066125A1 (es) |
AU (1) | AU2008240359B2 (es) |
BR (1) | BRPI0810411B8 (es) |
CA (1) | CA2684447C (es) |
CL (1) | CL2008001076A1 (es) |
CO (1) | CO6260093A2 (es) |
CU (1) | CU23813A3 (es) |
DK (1) | DK2146779T3 (es) |
DO (1) | DOP2009000248A (es) |
EA (1) | EA016679B1 (es) |
EC (1) | ECSP099694A (es) |
ES (1) | ES2593486T3 (es) |
GE (1) | GEP20125581B (es) |
GT (1) | GT200900272A (es) |
HK (2) | HK1200450A1 (es) |
IL (3) | IL201468A (es) |
MA (1) | MA31319B1 (es) |
MX (1) | MX2009011090A (es) |
NI (1) | NI200900190A (es) |
NZ (1) | NZ580372A (es) |
PA (1) | PA8777101A1 (es) |
PE (1) | PE20090434A1 (es) |
TN (1) | TN2009000428A1 (es) |
TW (1) | TWI369205B (es) |
UA (1) | UA97834C2 (es) |
UY (1) | UY31026A1 (es) |
WO (1) | WO2008129380A1 (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2146779T3 (en) * | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
UY31714A (es) * | 2008-03-20 | 2009-11-10 | Boehringer Ingelheim Int | Preparación selectiva de pirimidinas sustituidas |
US8372974B2 (en) * | 2008-03-20 | 2013-02-12 | Boehringer Ingelheim International Gmbh | Regioselective preparation of substituted pyrimidines |
WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
EA201100436A1 (ru) * | 2008-09-03 | 2011-10-31 | Байер Кропсайенс Аг | Гетероциклически замещенные анилинопиримидины в качестве фунгицидов |
UY32240A (es) * | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
JP2010111702A (ja) * | 2009-02-16 | 2010-05-20 | Tetsuya Nishio | 複素環化合物、その製造法および用途 |
CN101812016B (zh) * | 2009-02-23 | 2013-01-16 | 浙江海翔药业股份有限公司 | 一种制备依托昔布中间体-6-甲基烟酸及其酯的方法 |
EP2261211A1 (en) * | 2009-05-20 | 2010-12-15 | Université de Lille 2 Droit et Santé | 1,4-dihydropyridine derivatives and their uses |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
EP2438066A2 (en) | 2009-06-05 | 2012-04-11 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
EP2464633A1 (en) * | 2009-08-14 | 2012-06-20 | Boehringer Ingelheim International GmbH | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
ES2535116T3 (es) | 2010-03-04 | 2015-05-05 | Cellzome Limited | Derivados de urea sustituida con morfolino como inhibidores de mtor |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
CN105837519A (zh) * | 2010-06-04 | 2016-08-10 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
JP5937111B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited | Fak阻害剤 |
AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
CN105001165B (zh) | 2011-04-22 | 2020-06-23 | 西格诺药品有限公司 | 取代的二氨基嘧啶其组合物,和用其治疗的方法 |
RU2564419C1 (ru) * | 2011-07-28 | 2015-09-27 | Целльзом Лимитид | Гетероциклические аналоги пиримидина в качестве ингибиторов jak |
AU2012288892B2 (en) * | 2011-07-28 | 2016-04-21 | Cellzome Limited | Heterocyclyl pyrimidine analogues as JAK inhibitors |
AU2012311458B2 (en) | 2011-09-21 | 2016-02-04 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mTOR inhibitors |
US9242993B2 (en) | 2011-10-07 | 2016-01-26 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
CN104169272A (zh) | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | 作为激酶抑制剂的嘧啶-2,4-二胺衍生物 |
CA2865420C (en) * | 2012-03-06 | 2020-06-02 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
US9296725B2 (en) | 2012-05-24 | 2016-03-29 | Cellzome Limited | Heterocyclyl pyrimidine analogues as TYK2 inhibitors |
KR20220130251A (ko) * | 2014-01-09 | 2022-09-26 | 베라스템, 인코포레이티드 | 비정상적 세포 성장의 치료를 위한 조성물 및 방법 |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
EP3102232B1 (en) | 2014-02-07 | 2020-02-05 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
KR20170002623A (ko) | 2014-05-14 | 2017-01-06 | 화이자 인코포레이티드 | 피라졸로피리딘 및 피라졸로피리미딘 |
JP6762940B2 (ja) | 2014-12-16 | 2020-09-30 | シグナル ファーマシューティカルズ,エルエルシー | 2−(tert−ブチルアミノ)−4−((1R,3R,4R)−3−ヒドロキシ−4−メチルシクロヘキシルアミノ)−ピリミジン−5−カルボキサミドの製剤 |
JP6903577B2 (ja) | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ,エルエルシー | 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法 |
WO2016100452A2 (en) * | 2014-12-17 | 2016-06-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US20180022710A1 (en) | 2015-01-29 | 2018-01-25 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
JP2018519327A (ja) | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドVerastem,Inc. | 治療用組成物、組合せ物および使用の方法 |
CN107922287B (zh) | 2015-07-24 | 2021-04-09 | 细胞基因公司 | 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体 |
CN105111204B (zh) * | 2015-08-14 | 2016-09-14 | 天津小新医药科技有限公司 | 吡啶盐类酪氨酸激酶抑制剂、制备方法及其用途 |
CN105153150B (zh) * | 2015-08-14 | 2016-09-14 | 天津小新医药科技有限公司 | 一类吡啶盐类jak抑制剂、制备方法及其用途 |
CN105503860B (zh) * | 2015-10-13 | 2017-03-01 | 天津小新医药科技有限公司 | 一类腈基取代的吡啶盐类jak抑制剂、制备方法及其用途 |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
CN106279011A (zh) * | 2016-08-16 | 2017-01-04 | 成都百事兴科技实业有限公司 | 一种2,4‑二羟基‑6‑甲基烟酸乙酯的制备方法 |
WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
JP2021517589A (ja) | 2018-03-12 | 2021-07-26 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用 |
RU2761825C1 (ru) * | 2018-05-07 | 2021-12-13 | Хинова Фармасьютикалс Инк. | Соединения дейтерированного дефактиниба и их применение |
WO2020006724A1 (zh) * | 2018-07-05 | 2020-01-09 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
AU2019348011A1 (en) * | 2018-09-27 | 2021-02-11 | Dana-Farber Cancer Institute, Inc. | Degradation of FAK or FAK and ALK by conjugation of FAK and ALK inhibitors with E3 ligase ligands and methods of use |
BR112021012682A2 (pt) * | 2018-12-27 | 2021-09-08 | Hinova Pharmaceuticals Inc. | Inibidor de fak e combinação de fármaco do mesmo |
JP2022547358A (ja) | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
CN112592318B (zh) * | 2020-12-12 | 2022-05-03 | 贵州医科大学 | 2-(4-甲氨酰基)苯胺基-4-氨基嘧啶衍生物及应用 |
CN112624966B (zh) * | 2020-12-25 | 2022-12-23 | 杭州澳赛诺生物科技有限公司 | 一种2-氨甲基-4-甲基-5-吡啶羧酸的合成方法 |
CA3208625A1 (en) * | 2021-01-18 | 2022-07-21 | Hinova Pharmaceuticals Inc. | Synthesis method for aminopyrimidine fak inhibitor compound |
CA3220357A1 (en) * | 2021-05-25 | 2022-12-01 | Jing Li | Pharmaceutical composition for treatment of cancer and use thereof |
CN113372334B (zh) * | 2021-05-25 | 2022-05-03 | 贵州医科大学 | 2-(4-甲氨酰基)苯胺基-4-氨基-5-三氟甲基嘧啶衍生物及其应用 |
CN114716385B (zh) * | 2022-04-08 | 2024-03-12 | 北京师范大学 | 靶向粘着斑激酶的化合物及制备方法和应用 |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
WO2024071371A1 (ja) * | 2022-09-30 | 2024-04-04 | ユビエンス株式会社 | 複素環式化合物 |
CN117105916B (zh) * | 2023-10-23 | 2024-01-16 | 希格生科(深圳)有限公司 | 苯并呋喃类化合物及其医药用途 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507146A (en) | 1982-12-28 | 1985-03-26 | Ciba-Geigy Corporation | 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | 1n−アルキル−n−アリールピリミジンアミンおよびその誘導体 |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
JP3053222B2 (ja) | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体 |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
TR199900066T2 (xx) | 1996-07-18 | 1999-04-21 | Pfizer Inc. | Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri |
SK21499A3 (en) | 1996-08-23 | 2000-05-16 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
DE69817801T2 (de) | 1997-02-03 | 2004-03-11 | Pfizer Products Inc., Groton | Arylsulfonylhydroxamsäurederivate |
BR9807824A (pt) | 1997-02-07 | 2000-03-08 | Pfizer | Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz |
EP0960098A1 (en) | 1997-02-11 | 1999-12-01 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
TR200000368T2 (tr) | 1997-08-08 | 2000-07-21 | Pfizer Products Inc. | Ariloksiariarilsülfonilamino hidroksamik asit türevleri. |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
NZ506417A (en) | 1998-02-17 | 2003-05-30 | Tularik Inc | Anti-viral pyrimidine derivatives |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
IT1302431B1 (it) * | 1998-08-12 | 2000-09-05 | Alasi Di Arcieri Franco & C S | Dispositivo di controllo di accessi in rete tramite il riconoscimentoveloce di trame applicative che soddisfano un insieme di regole |
DE69915004T2 (de) | 1998-11-05 | 2004-09-09 | Pfizer Products Inc., Groton | 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate |
CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US7034019B2 (en) | 2000-05-08 | 2006-04-25 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
AU783981C (en) | 2000-05-08 | 2007-05-03 | Janssen Pharmaceutica N.V. | HIV replication inhibitors |
US6630469B2 (en) * | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
US6853233B1 (en) * | 2000-09-13 | 2005-02-08 | Infineon Technologies Ag | Level-shifting circuitry having “high” output impedance during disable mode |
IT1319686B1 (it) | 2000-12-12 | 2003-10-23 | C D Farmasint S R L | Procedimento di preparazione di citalopram. |
MXPA03005610A (es) * | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
JP4291135B2 (ja) * | 2001-05-29 | 2009-07-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Cdk阻害性ピリミジン、それらの製造および薬剤としての使用 |
WO2002102783A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2002102313A2 (en) * | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
WO2003032997A1 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US7008378B2 (en) * | 2002-03-07 | 2006-03-07 | Dean Melanie A | Patient conditional diagnosis assessment and symptom tracking system |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
WO2003095448A1 (en) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
WO2004002964A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
SG176311A1 (en) | 2002-07-29 | 2011-12-29 | Rigel Pharmaceuticals | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
JP2006507302A (ja) | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | キナーゼ阻害剤 |
JP2006508997A (ja) | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用 |
SE0203820D0 (sv) * | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | chemical compounds |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
ES2338545T3 (es) * | 2002-12-20 | 2010-05-10 | Pfizer Products Inc. | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
CA2513527C (en) | 2003-02-07 | 2012-08-14 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
WO2005003103A2 (en) | 2003-06-30 | 2005-01-13 | Astrazeneca Ab | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases |
US20070161637A1 (en) | 2003-07-22 | 2007-07-12 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
JP4607879B2 (ja) | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン |
BRPI0414059B8 (pt) * | 2003-09-05 | 2021-05-25 | Pfizer Prod Inc | síntese seletiva de pirimidinas substituídas em cf3 |
US7363505B2 (en) * | 2003-12-03 | 2008-04-22 | Pen-One Inc | Security authentication method and system |
JP4099212B2 (ja) * | 2004-05-14 | 2008-06-11 | ファイザー・プロダクツ・インク | 異常な細胞増殖を処置するためのピリミジン誘導体 |
WO2005111022A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidines derivatives for the treatment of abnormal cell growth |
EP1758887A1 (en) | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1756090A1 (en) * | 2004-05-14 | 2007-02-28 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
WO2005121121A2 (en) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
AU2005262322B2 (en) | 2004-07-01 | 2012-07-26 | Synta Pharmaceuticals Corp. | 2-substituted heteroaryl compounds |
US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
RU2007114080A (ru) * | 2004-10-13 | 2008-11-27 | Вайет (Us) | N-бензилсульфонил-замещенные аналоги анилинопиримидина |
TW200630363A (en) | 2004-11-10 | 2006-09-01 | Synta Pharmaceuticals Corp | Process for preparing trisubstituted pyrimidine compounds |
TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
PL1912636T3 (pl) | 2005-07-21 | 2015-02-27 | Ardea Biosciences Inc | N-(aryloamino)sulfonamidowe inhibitory mek |
EP1966192B1 (en) * | 2005-12-01 | 2012-10-17 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
CA2634646C (en) | 2005-12-21 | 2012-04-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
DK2146779T3 (en) * | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
-
2008
- 2008-04-07 DK DK08719431.2T patent/DK2146779T3/en active
- 2008-04-07 AP AP2009005010A patent/AP2009005010A0/xx unknown
- 2008-04-07 CN CN201410067096.3A patent/CN103951658B/zh active Active
- 2008-04-07 UA UAA200910461A patent/UA97834C2/ru unknown
- 2008-04-07 WO PCT/IB2008/000845 patent/WO2008129380A1/en active Application Filing
- 2008-04-07 GE GEAP200811513A patent/GEP20125581B/en unknown
- 2008-04-07 CA CA2684447A patent/CA2684447C/en active Active
- 2008-04-07 NZ NZ580372A patent/NZ580372A/en unknown
- 2008-04-07 MX MX2009011090A patent/MX2009011090A/es active IP Right Grant
- 2008-04-07 BR BRPI0810411A patent/BRPI0810411B8/pt active IP Right Grant
- 2008-04-07 AU AU2008240359A patent/AU2008240359B2/en active Active
- 2008-04-07 JP JP2010503606A patent/JP4782239B2/ja active Active
- 2008-04-07 KR KR1020097023931A patent/KR101132880B1/ko active IP Right Grant
- 2008-04-07 ES ES08719431.2T patent/ES2593486T3/es active Active
- 2008-04-07 EA EA200901250A patent/EA016679B1/ru not_active IP Right Cessation
- 2008-04-07 EP EP08719431.2A patent/EP2146779B1/en active Active
- 2008-04-07 CN CN200880019325.7A patent/CN101678215B/zh active Active
- 2008-04-15 CL CL200801076A patent/CL2008001076A1/es unknown
- 2008-04-16 UY UY31026A patent/UY31026A1/es not_active Application Discontinuation
- 2008-04-16 PA PA20088777101A patent/PA8777101A1/es unknown
- 2008-04-17 US US12/105,151 patent/US7928109B2/en active Active
- 2008-04-17 TW TW097113908A patent/TWI369205B/zh active
- 2008-04-17 PE PE2008000674A patent/PE20090434A1/es not_active Application Discontinuation
- 2008-04-18 AR ARP080101626A patent/AR066125A1/es not_active Application Discontinuation
-
2009
- 2009-10-12 IL IL201468A patent/IL201468A/en not_active IP Right Cessation
- 2009-10-16 TN TNP2009000428A patent/TN2009000428A1/fr unknown
- 2009-10-16 CU CU20090175A patent/CU23813A3/es not_active IP Right Cessation
- 2009-10-16 MA MA32288A patent/MA31319B1/fr unknown
- 2009-10-16 CO CO09115844A patent/CO6260093A2/es not_active Application Discontinuation
- 2009-10-16 EC EC2009009694A patent/ECSP099694A/es unknown
- 2009-10-16 GT GT200900272A patent/GT200900272A/es unknown
- 2009-10-16 NI NI200900190A patent/NI200900190A/es unknown
- 2009-10-16 DO DO2009000248A patent/DOP2009000248A/es unknown
-
2010
- 2010-05-19 HK HK15100919.1A patent/HK1200450A1/xx unknown
- 2010-05-19 HK HK10104930.3A patent/HK1136985A1/xx unknown
-
2011
- 2011-03-11 US US13/045,923 patent/US8247411B2/en active Active
-
2012
- 2012-07-24 US US13/557,049 patent/US8440822B2/en active Active
-
2013
- 2013-03-29 US US13/853,483 patent/US20140100368A1/en not_active Abandoned
-
2014
- 2014-05-08 IL IL232511A patent/IL232511B/en active IP Right Grant
- 2014-11-24 US US14/552,153 patent/US20150080368A1/en not_active Abandoned
-
2016
- 2016-01-19 US US15/000,944 patent/US20160130250A1/en not_active Abandoned
- 2016-09-12 US US15/263,041 patent/US20170001981A1/en not_active Abandoned
-
2017
- 2017-04-20 US US15/492,719 patent/US20170327485A1/en not_active Abandoned
-
2018
- 2018-04-05 US US15/946,117 patent/US10450297B2/en active Active
- 2018-07-12 IL IL260560A patent/IL260560B/en active IP Right Grant
-
2019
- 2019-09-11 US US16/567,675 patent/US20200002310A1/en not_active Abandoned
-
2021
- 2021-08-27 US US17/458,862 patent/US20220251066A1/en not_active Abandoned
-
2023
- 2023-03-15 US US18/121,809 patent/US20240109862A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090434A1 (es) | Derivados de sulfonil amida como inhibidores de quinasas | |
PE20110308A1 (es) | 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa | |
PE20090606A1 (es) | Nuevos inhibidores de catepsina c y uso | |
PE20090641A1 (es) | Amidas heterociclicas | |
PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
PE20070462A1 (es) | Compuestos derivados de fenilaminopropanol | |
PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
PE20121354A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
PE20090837A1 (es) | Nuevos compuestos quimicos | |
PE20081404A1 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion | |
PE20091092A1 (es) | Compuestos heterociclicos como inhibidores de la via hedgehog | |
PE20030968A1 (es) | Derivados de 5-feniltiazol como inhibidores de cinasas | |
ATE450532T1 (de) | Pyridinyl- oder pyrimidinylthiazole mit proteinkinasehemmender wirkung | |
PE20090423A1 (es) | Compuestos moduladores de sirtuina | |
PE20061117A1 (es) | DERIVADOS DE FENILGLICINAMIDA COMO INHIBIDORES DEL FACTOR VIIa | |
PE20081351A1 (es) | Derivados de quinazolina como agentes anticancerigenos | |
PE20070359A1 (es) | Inhibidores de pirimidinilpirazol de aurora quinasas | |
PE20080061A1 (es) | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
PE20061124A1 (es) | Compuestos y derivados de dibencil amina | |
PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |